Andrew Seidman, MD

home / authors / andrew-seidman-md

Articles

Patients Prefer Subcutaneous Regimen for HER2-Positive Breast Cancer

Patients Prefer Subcutaneous Regimen for HER2-Positive Breast Cancer

January 6th 2022

Andrew Seidman, MD, discusses the PHranceSCa trial of patient preference for intravenous versus subcutaneous trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer.